Skip to main content
. Author manuscript; available in PMC: 2024 Jan 5.
Published in final edited form as: Clin Cancer Res. 2023 Jul 5;29(13):2410–2418. doi: 10.1158/1078-0432.CCR-23-0252

Figure 1. Predicted probability of SIOP Grade≥2 hearing loss with and without NAC.

Figure 1.

From multivariable logistic regression model for risk of developing SIOP Grade ≥2 hearing loss at the end of chemotherapy timepoint (i.e., after all cisplatin and prior to autologous stem cell transplant [as applicable]), the probability of developing hearing loss was reduced in patients receiving N-acetylcysteine (NAC) versus those with observation-only in the control arm. This difference was present within all three age groups and across the range of cisplatin dosing (mg/m2/day): (A) less than 5 years old, (B) 6-10 years old, (C) 11 years and older.